Novartis ends Tekturna trial on safety concerns - FiercePharma
Bad news for Novartis' ($NVS) blood pressure med TEKTURNA (aka Rasilez). The drug company has decided to end a trial evaluating the med in Type 2 diabetes patients with renal impairment who are also
Tekturna HCT Oral Reviews and User Ratings: Effectiveness, Ease of Use, and Satisfaction
Find user ratings and reviews for TEKTURNA HCT Oral on WebMD including side effects and drug interactions, medication effectiveness, ease of use and satisfaction
Tekturna HCT Drug and Medication User Reviews on RxList
Users share their experience with
TEKTURNA HCT and comment on drug side effects, effectiveness, and treatment knowledge
Aliskiren – Wikipedia
mit Hydrochlorothiazid: Rasilez HCT (D, A, CH), TEKTURNA HCT (USA); mit Amlodipin: .... Wikipedia® ist eine eingetragene Marke der Wikimedia Foundation Inc.
Aliskiren - Wikipedia, the free encyclopedia
Aliskiren (INN) (trade names TEKTURNA, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication ...
Novartis announces Aliskiren will continue to be available to appropriate patients, as FDA interim assessment is concluded; product information updated
19 Apr 2012... to be voluntarily withdrawn from the US market as of July 20, 2012. Basel ... The US Prescribing Information has been updated for TEKTURNA, ...
Tekturna New FDA Drug Approval | CenterWatch
TEKTURNA (aliskiren): For the treatment of hypertension. New approved drug details including side effects, uses and general information.
Tekturna And Other Aliskiren Related Blood Pressure Medications Can Cause Renal Failure, Kidney Complications, And Strokes - Drug Injury Watch
Concomitant Use Of TEKTURNA With ACE Inhibitors And ARBs Contraindicated In Patients With Diabetes; Plus An FDA Caution Regarding Renal Impairment (Posted by Tom Lamb at DrugInjuryWatch.com) TEKTURNA (aliskiren) was approved by the FDA for marketing in March 2007 after it was evaluated for safety in 6,460 patients, and only 1250 patients were treated for longer than 1 year. As we have learned too often with many newly marketed drugs, the true incidence of serious adverse events may not be realized until many thousands or millions of exposures have occurred in a patient population less homogeneous than the group participating in the premarketing trials. And that scenario may be the case with TEKTURNA as well as the other aliskiren related drugs: TEKTURNA HCT (aliskiren hemifumarate and hydrochlorothiazide) Tekamlo (aliskiren hemifumarate and amlodipine besylate) Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide Valturna (aliskiren hemifumarate and valsartan). NOTE: Novartis stopped marketing Valturna in July 2012, i.e., withdrawn from the market. TEKTURNA is taken orally and prescribed to treat high blood pressure (hypertension). In December 2011 the drug company Novartis announced the termination of its clinical ALTITUDE study of TEKTURNA after researchers observed an increased number of serious side effects in the study’s...
Novartis Under U.S. Investigation for Tekturna Marketing - Bloomberg
Novartis AG, Europe’s biggest drugmaker by sales, said U.S. prosecutors are investigating the company’s marketing of products including the hypertension medicine TEKTURNA.